Related Experiment Video
Updated: Sep 29, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
New Generation Gepants: Migraine Acute and Preventive Medications
David Moreno-Ajona1,2, María Dolores Villar-Martínez1,2, Peter J Goadsby1,2,3
1Basic and Clinical Neurosciences, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 9PJ, UK.
Abstract:
Migraine is a debilitating disease whose clinical and social impact is out of debate. Tolerability issues, interactions, contraindications, and inefficacy of the available medications make new options necessary. The calcitonin-gene-related peptide (CGRP) pathway has shown its importance in migraine pathophysiology and specific medications targeting this have become available. The first-generation CGRP receptor antagonists or gepants, have undergone clinical trials but their development was stopped because of hepatotoxicity. The new generation of gepants, however, are efficacious, safe, and well tolerated as per recent clinical trials. This led to the FDA-approval of rimegepant, ubrogepant, and atogepant. The clinical trials of the available gepants and some of the newer CGRP-antagonists are reviewed in this article.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Blockers
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Angle Closure Glaucoma: Treatment
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

